Key Takeaways
- Blast.Club raised $5.0M (Seed) from TruVenturo, Blast.Club.
- Sector: Healthcare Healthtech & Medtech.
- Geography: Germany.
Analysis
Berlin-based cryonics company Tomorrow.Bio has successfully completed the first close of a €5 million equity funding round, marking a significant milestone in its mission to revolutionize life preservation technology.
"Companies like Tomorrow.Bio are at the forefront of visionary longevity approaches," said Nils Regge. "We're thrilled to support these moonshot endeavors that have the potential to significantly extend human lifespan and offer substantial business opportunities."
Anthony Bourbon, Founder and CEO of Blast.Club, added, "Tomorrow.Bio's cutting-edge technology is redefining our perception of life and death. The founders' ambitious yet realistic vision positions the company as a potential future leader in medicine."
Strategic Expansion into the U.S.
The newly acquired funds will facilitate Tomorrow.Bio's expansion into the United States, with initial operations planned in New York, California, and Florida. This move represents the first phase of a nationwide rollout anticipated by mid-2025.
Dr. Emil Kendziorra, Founder and CEO of Tomorrow.Bio, expressed enthusiasm about the expansion: "We're extremely pleased to have found visionary investors to continue our long-term mission. Not only by expanding our coverage to the U.S. but also by doubling down on R&D to further improve preservation quality and stay far ahead of all competition."
Advancements in Cryopreservation Technology
Founded in 2020 by Dr. Emil Kendziorra and Fernando Azevedo Pinheiro, Tomorrow.Bio offers cryopreservation services for humans and animals. The company has cryopreserved 20 individuals and 10 pets, with over 800 more registered, and a total contract value exceeding €160 million.
Cryopreservation involves cooling the body to minus 196°C to halt biological processes. Tomorrow.Bio employs cryo-ambulances to retrieve individuals after legal death, initiating the cooling process during transport to a facility in Switzerland. The company’s “standby teams” currently operate from Berlin and Zurich, with plans to establish additional locations in Europe and the U.S.
As part of its U.S. expansion, Tomorrow.Bio plans to establish partner medical teams in at least three new locations, positioning itself as the first company to offer local teams capable of beginning the cryopreservation process immediately after legal death.
The company collaborates with its sister organization, the European Biostasis Foundation, based in Rafz, Switzerland, where cryopreserved individuals are stored in vacuum-insulated steel containers filled with liquid nitrogen, operating without electricity to maintain low temperatures.
Pioneering the Future of Medicine
Tomorrow.Bio's innovative approach to cryonics, combined with its strategic expansion and commitment to research and development, positions the company as a potential leader in the emerging field of life preservation technology. By bridging the gap between current medical capabilities and future advancements, Tomorrow.Bio offers a glimpse into a future where extending human life beyond its natural limits becomes a tangible possibility.